These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 29926342

  • 1. Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms.
    Xu J, Li Y, Xu X, Zhang J, Zhang Y, Yu X, Huang D.
    Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
    [Abstract] [Full Text] [Related]

  • 2. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
    Qiao Z, Zhang J, Jin X, Huo L, Zhu Z, Xing H, Li F.
    Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
    [Abstract] [Full Text] [Related]

  • 3. Microcystic Serous Cystadenoma Masquerading as Pancreatic Neuroendocrine Tumor on 99m Tc-HYNIC-TOC SPECT/CT.
    Cai W, Dong Y, Zhao T, Dong A, Zhao Q.
    Clin Nucl Med; 2024 Feb 01; 49(2):e87-e89. PubMed ID: 38048519
    [Abstract] [Full Text] [Related]

  • 4. Incremental value of 99mTc-HYNIC-TOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours.
    Trogrlic M, Težak S.
    Nuklearmedizin; 2017 Jun 12; 56(3):97-107. PubMed ID: 28164207
    [Abstract] [Full Text] [Related]

  • 5. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J.
    J Nucl Med; 2008 Jul 12; 49(7):1060-5. PubMed ID: 18552141
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of 99mTc-HYNIC-TOC SPECT/CT for the diagnosis primary small cell neuroendocrine carcinomas of the nasal cavity and paranasal sinuses.
    Chen H, Li Y, Gao X, Shen X.
    Clin Imaging; 2018 Jul 12; 52():365-369. PubMed ID: 30248495
    [Abstract] [Full Text] [Related]

  • 7. Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours.
    Malarz MM, Birkenfeld B, Piwowarska-Bilska H.
    Nucl Med Rev Cent East Eur; 2024 Jul 12; 27(0):31-35. PubMed ID: 39162352
    [Abstract] [Full Text] [Related]

  • 8. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
    Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R, Profanter C, Moncayo R, Virgolini I.
    Q J Nucl Med Mol Imaging; 2005 Sep 12; 49(3):237-44. PubMed ID: 16172569
    [Abstract] [Full Text] [Related]

  • 9. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
    Sergieva S, Robev B, Dimcheva M, Fakirova A, Hristoskova R.
    Nucl Med Rev Cent East Eur; 2016 Sep 12; 19(2):81-7. PubMed ID: 27479885
    [Abstract] [Full Text] [Related]

  • 10. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Sep 12; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 11. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
    Artiko V, Sobic-Saranovic D, Pavlovic S, Petrovic M, Zuvela M, Antic A, Matic S, Odalovic S, Petrovic N, Milovanovic A, Obradovic V.
    J BUON; 2012 Sep 12; 17(3):537-42. PubMed ID: 23033296
    [Abstract] [Full Text] [Related]

  • 12. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep 12; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 13. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
    Gómez M, Ferrando R, Vilar J, Hitateguy R, López B, Moreira E, Kapitán M, De Lima F, Agüero B, Gabriela Villegas M, Urdaneta N, Gutiérrez E, Battegazzore A, Bayardo K, Silveira A, Lago G, Páez A.
    Acta Gastroenterol Latinoam; 2010 Dec 12; 40(4):332-8. PubMed ID: 21381408
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M, Tezak S.
    Nucl Med Rev Cent East Eur; 2016 Dec 12; 19(2):74-80. PubMed ID: 27479884
    [Abstract] [Full Text] [Related]

  • 15. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
    Li F, Chen LB, Jing HL, Du YR, Chen F.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct 12; 25(5):563-6. PubMed ID: 14650159
    [Abstract] [Full Text] [Related]

  • 16. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors.
    Li Y, Xu J, Xu X, Zhang J, Zhang Y.
    Nucl Med Commun; 2019 Oct 12; 40(10):1005-1010. PubMed ID: 31365494
    [Abstract] [Full Text] [Related]

  • 17. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.
    Al-Chalabi H, Cook A, Ellis C, Patel CN, Scarsbrook AF.
    Clin Radiol; 2018 Jun 12; 73(6):527-534. PubMed ID: 29397911
    [Abstract] [Full Text] [Related]

  • 18. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
    Parisella MG, Chianelli M, D'Alessandria C, Todino V, Mikolajczak R, Papini E, Dierckx RA, Scopinaro F, Signore A.
    Q J Nucl Med Mol Imaging; 2012 Feb 12; 56(1):90-8. PubMed ID: 21068709
    [Abstract] [Full Text] [Related]

  • 19. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
    Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2005 Dec 12; 32(12):1440-51. PubMed ID: 16133384
    [Abstract] [Full Text] [Related]

  • 20. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.
    Reilly C, Gemmell AJ, McLaughlin IM, Fleming R, Reed N, McIntosh D, Nicol A.
    Nucl Med Commun; 2021 Aug 01; 42(8):935-939. PubMed ID: 33741866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.